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by widespread drug usage, and we emphasize that targeted 
treatment has the potential advantage of prolonging the use-
ful lifespan of a drug such as praziquantel. 
The conclusion of our modeling analysis is that there 
may be only a 7- to 10-year period during which control 
projects will  consistent, drug-mediated reductions in worm 
burden. It is essential, therefore, that planners anticipate 
eventual drug failure and incorporate, as part of an inte-
grated infection-management system, nondrug interventions 
that will prolong drug usefulness. Prevention of transmis-
sion and not just development of newer drugs will finally 
provide the best form of “therapy.”
C. H. King,* J.H. Ouma,† and E.M. Muchiri†
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Reiter Syndrome Following Protracted Symptoms of 
Cyclospora Infection
To the Editor: I read with interest and some dismay the 
report by Connor et al. on Reiter syndrome following pro-
tracted symptoms of Cyclospora infection (1). Wallace and 
Weisman summarized quite eloquently the history of 
“Reiter’s syndrome” (2). It is now well documented that the 
syndrome had been described several hundred years before 
Reiter’s publication. More importantly, Hans Reiter was a 
war criminal, having participated in or supervised medical 
“experiments” conducted on concentration camp inmates by 
the Nazis. Wallace and Weisman suggest “Reiter does not 
deserve eponymous distinction. The disorder should be 
renamed ‘reactive cutaneo-arthropathy,’ or ‘reactive arthri-
tis’ syndrome.” I agree with this proposal, have made it my 
practice, and urge this journal and my colleagues to do the 
same.
Victor S. Sloan
Robert Wood Johnson Medical School
New Brunswick, New Jersey, USA
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